- OUTLOOK
A simple test could extend cystic-fibrosis treatments to those left behind
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature 583, S5 (2020)
doi: https://doi.org/10.1038/d41586-020-02107-9
This article is part of Nature Outlook: Cystic fibrosis, an editorially independent supplement produced with the financial support of third parties. About this content.
References
Taylor-Cousar, J. L. et al. ERJ Open Res. 5, 00082-2019 (2019).
Fidler, M. C., Beusmans, J., Panorchan, P. & Van Goor, F. J. Cyst. Fibros. 16, 41–44 (2017).
Mall, M. A., Mayer-Hamblett, N. & Rowe, S. M. Am. J. Respir. Crit. Care Med. 201, 1193–1208 (2020).
Kim, J. et al. Sci. Rep. 8, 16233 (2018).
Cystic fibrosis drugs target the malformed proteins at the root of the disease
In utero intervention to stem the damage of cystic fibrosis
Bacteria-eating viruses could provide a route to stability in cystic fibrosis
The gender gap in cystic fibrosis
Gene therapy could offer an inclusive cure for cystic fibrosis
The coronavirus pandemic has forced rapid changes in care protocols for cystic fibrosis
Living, breathing proof
How much protein function needs to be restored in cystic fibrosis?
Research round-up: Cystic fibrosis
